Search research articles
Contact Us
Filters
Showing results (391-400 of 480) with videos related to
Page
of 48
Sort By:
Blood
|
May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M Ross, Susan Branford, John F Seymour, et al.
Clinical Chemistry
|
March 9, 2013
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale
Helen E White, John Hedges, Israel Bendit, et al.
Blood
|
July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Susan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
British Journal of Haematology
|
March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
David M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Blood
|
August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Nature Communications
|
October 16, 2025
Noise-aware training of neuromorphic dynamic device networks
Luca Manneschi, Ian T Vidamour, Kilian D Stenning, et al.
Blood
|
August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford, Linda Fletcher, Nicholas C P Cross, et al.
Blood
|
March 22, 2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford, David T Yeung, David M Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy
Leyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Blood
|
February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
Page
of 48
Search research articles
Search
Showing results (391-400 of 480) with videos related to
Sort By:
Page
of 48
Blood
|
May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M Ross, Susan Branford, John F Seymour, et al.
Clinical Chemistry
|
March 9, 2013
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale
Helen E White, John Hedges, Israel Bendit, et al.
Blood
|
July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Susan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
British Journal of Haematology
|
March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
David M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Blood
|
August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Nature Communications
|
October 16, 2025
Noise-aware training of neuromorphic dynamic device networks
Luca Manneschi, Ian T Vidamour, Kilian D Stenning, et al.
Blood
|
August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford, Linda Fletcher, Nicholas C P Cross, et al.
Blood
|
March 22, 2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford, David T Yeung, David M Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy
Leyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Blood
|
February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
Page
of 48